Conference PaperPDF Available

SAT0124 Aortic stiffness and time to wave reflection are associated with left ventricular diastolic dysfunction measures in rheumatoid arthritis

Authors:

Abstract

Background Patients with rheumatoid arthritis (RA) experience an increased frequency of heart failure with a preserved ejection fraction (HFpEF) (1). The treatment of HFpEF is currently suboptimal. Elucidation of the underlying pathophysiological mechanisms of HFpEF may provide potential targets for its management. Diastolic dysfunction often precedes the progression to HFpEF (2). Abnormalities in aortic function contribute to diastolic dysfunction in non-RA populations (3,4). Objectives The aim of this study was to determine whether impaired aortic function is associated with left ventricular diastolic dysfunction in RA. Methods Arterial function was determined by applanation tonometry using SphygmoCor software and left ventricular diastolic function was assessed by echocardiography in 176 patients with RA. Markers of arterial function included carotid femoral pulse wave velocity (PWV), central systolic and pulse pressure, pulse pressure amplification and the magnitude and timing of the forward and reflected waves. Markers of diastolic function included the ratio of early-to-late transmitral blood flow velocity (E/A), the ratio of E to the mean of the lateral and septal wall myocardial tissue lengthening at the mitral annulus (e’)(E/e’) and the septal and lateral e’. Relationships of comprehensively evaluated arterial function with markers of LV diastolic function were determined in confounder adjusted multivariate regression models. Results The timing of the forward (Ft) and reflected (Rt) waves were each associated with E/A (Ft: partial r=0.20, p=0.02; Rt: partial r=0.30, p=0.001) and Rt was further associated with lateral e’ (partial r=0.36, p<0.0001) and septal e’ (partial r=0.36, p<0.0001); PWV was associated with E/e’ (partial r=0.18; p=0.03). Reflected wave timing was associated with two indices of impaired relaxation (E/A<0.8: OR (95% CI)=0.51 (0.29-0.91), p=0.01; lateral e’<10: OR (95% CI)=0.43 (0.26-0.71), p=0.001); PWV was associated with an increased left ventricular filling pressure (E/e’>12: OR (95% CI)=1.58 (1.04-2.38), p=0.03). Conclusions Aortic stiffness and time to wave reflection are associated with increased filling pressure and impaired relaxation of the left ventricle, respectively. The development of diastolic dysfunction in RA may be partly mediated by changes in large artery function. References [1] Davis JM, Roger VL, Crowson CS, et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheumatol 2008;58:2603-11. [2] Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001;37:1042-8. [3] Peterson VR, Woodiwiss AJ, Libhaber CD, et al. Cardiac diastolic dysfunction is associated with aortic wave reflection, but not stiffness in a predominantly young-to-middle-aged community sample. Am J Hypertens 2016;29:1148-57. [4] Cauwenberghs N, Knez J, Tikhonoff V, et al. Doppler indexes of left ventricular systolic and diastolic function in relation to the arterial stiffness in a general population. J Hypertens 2016;34:762-71. Disclosure of Interest None declared
disease activity in RA, although the effect of the other antibiotics on disease activ-
ity should be examined.
REFERENCES:
[1] Roszyk E, Puszczewicz M. Role of human microbiome and selected bacte-
rial infections in the pathogenesis of rheumatoid arthritis. Reumatologia
2017;55:242-50.
[2] Galli M, Antinori S, Atzeni F, et al. Recommendations for the management
of pulmonary fungal infections in patients with rheumatoid arthritis. Clin
Exp Rheumatol 2017;35:1018-28.
[3] Harigai M, Koike R, Miyasaka N, et al. Pneumocystis pneumonia associ-
ated with infliximab in Japan. N Engl J Med 2007;357:1874-6.
Acknowledgements: None.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2018-eular.2693
SAT0124 AORTIC STIFFNESS AND TIME TO WAVE REFLECTION
ARE ASSOCIATED WITH LEFT VENTRICULAR
DIASTOLIC DYSFUNCTION MEASURES IN
RHEUMATOID ARTHRITIS
A. M. Millen
1
, L. Mokotedi
1
,S.Gunter
1
,C.Robinson
1
, F. Michel
1
, A. J. Woodiwiss
1
,
L. Tsang
1
,G.R.Norton
1
, P. H. Dessein
2
.
1
School of Physiology, University of the
Witwatersrand, Parktown, Johannesburg, South Africa;
2
Free University Brussels,
Brussels, Belgium
Background: Patients with rheumatoid arthritis (RA) experience an increased
frequency of heart failure with a preserved ejection fraction (HFpEF) (1). The treat-
ment of HFpEF is currently suboptimal. Elucidation of the underlying pathophysio-
logical mechanisms of HFpEF may provide potential targets for its management.
Diastolic dysfunction often precedes the progression to HFpEF (2). Abnormalities
in aortic function contribute to diastolic dysfunction in non-RA populations (3,4).
Objectives: The aim of this study was to determine whether impaired aortic func-
tion is associated with left ventricular diastolic dysfunction in RA.
Methods: Arterial function was determined by applanation tonometry using
SphygmoCor software and left ventricular diastolic function was assessed by
echocardiography in 176 patients with RA. Markers of arterial function included
carotid femoral pulse wave velocity (PWV), central systolic and pulse pressure,
pulse pressure amplification and the magnitude and timing of the forward and
reflected waves. Markers of diastolic function included the ratio of early-to-late
transmitral blood flow velocity (E/A), the ratio of E to the mean of the lateral and
septal wall myocardial tissue lengthening at the mitral annulus (e)(E/e) and the
septal and lateral e. Relationships of comprehensively evaluated arterial function
with markers of LV diastolic function were determined in confounder adjusted mul-
tivariate regression models.
Results: The timing of the forward (Ft) and reflected (Rt) waves were each asso-
ciated with E/A (Ft: partial r=0.20, p=0.02; Rt: partial r=0.30, p=0.001) and Rt was
further associated with lateral e(partial r=0.36, p<0.0001) and septal e(partial
r=0.36, p<0.0001); PWV was associated with E/e(partial r=0.18; p=0.03).
Reflected wave timing was associated with two indices of impaired relaxation (E/
A<0.8: OR (95% CI)=0.51 (0.29-0.91), p=0.01; lateral e<10: OR (95% CI)=0.43
(0.26-0.71), p=0.001); PWV was associated with an increased left ventricular fill-
ing pressure (E/e>12: OR (95% CI)=1.58 (1.04-2.38), p=0.03).
Conclusions: Aortic stiffness and time to wave reflection are associated with
increased filling pressure and impaired relaxation of the left ventricle, respectively.
The development of diastolic dysfunction in RA may be partly mediated by
changes in large artery function.
REFERENCES:
[1] Davis JM, Roger VL, Crowson CS, et al. The presentation and outcome of
heart failure in patients with rheumatoid arthritis differs from that in the
general population. Arthritis Rheumatol 2008;58:2603-11.
[2] Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of sys-
tolic and diastolic function for incident congestive heart failure in the eld-
erly: the cardiovascular health study. J Am Coll Cardiol 2001;37:1042-8.
[3] Peterson VR, Woodiwiss AJ, Libhaber CD, et al. Cardiac diastolic dysfunc-
tion is associated with aortic wave reflection, but not stiffness in a predomi-
nantly young-to-middle-aged community sample. Am J Hypertens
2016;29:1148-57.
[4] Cauwenberghs N, Knez J, Tikhonoff V, et al. Doppler indexes of left ven-
tricular systolic and diastolic function in relation to the arterial stiffness in a
general population. J Hypertens 2016;34:762-71.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2018-eular.5090
SAT0125 THE IMPACT OF SELECTED COMORBIDITIES ON
TREATMENT OUTCOME IN PATIENTS WITH
RHEUMATOID ARTHRITIS: AN EXPLORATORY COHORT
STUDY.
A. Emamifar
1
, I. M. Jensen Hansen
2
.
1
Faculty of Health Sciences, University of
Southern Denmark, Odense;
2
Rheumatology, OUH, Svendborg Hospital,
Svendborg, Denmark
Background: Patients with Rheumatoid Arthritis (RA) may present with various
comorbidities resulting in worse treatment response.[1-2]
Objectives: To investigate the impact of selected comorbid diseases on RA out-
come with the aim of Disease Activity Score in 28 joints-C-Reactive Protein
(DAS28-CRP).
Methods: All our RA patients were included in this study. Patientsdemographics,
serology results and DAS28-CRP at the time of diagnosis and after 4 months of
treatment initiation were collected. Patientselectronic hospital records were eval-
uated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary
hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed
autoimmune diseases.
Results: 1035 RA patients were included. 63.4% were female, mean of age 67.1
years, mean of disease duration 9.6 years, 58.6% rheumatoid factor positive and
51.3% anti-cyclic citrullinated peptide positive. The observed prevalence of thy-
roid diseases was 11.8%, DM 10.4%, primary hyperparathyroidism 2.8%, vitamin
B12 deficiency 5.8%, and other diagnosed autoimmune diseases 1.6%. There
were significant associations between presence of thyroid diseases and female
gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism
and longer disease duration (p=0.002); other diagnosed autoimmune diseases
and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases
(p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly
poorer initial response to the RA treatment compared to patients with isolated RA.
Univariate analyses revealed that age, presence of thyroid diseases, presence of
other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis
were significantly associated with ΔDAS28-CRP. Additionally, multivariate analy-
sis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to
the presence of thyroid diseases (unstandardized regression coefficient (standard
error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune dis-
eases (-0.537(0.208),p=0.010). (table1)
Table 1. Univariate and multivariate analysis of risk factors for ΔDAS28-CRP.
Variables Univariate
analysis
Multivariate
analysis
Backward
analysis
Gender 0.028 (0.066) 0.058 (0.056)
Age 0.007 (0.002)** 0.003 (0.002)
Disease
duration
0.000 (0.003) - 0.003 (0.003)
IgM- rheumatoid
factor
-0.055 (0.065) 0.014 (0.068)
Anti-
cyclic
citrullinated
peptide
antibody
-0.098 (0.065) -0.041 (0.068)
Antinuclear
antibody
0.003 (0.086) -0.042 (0.067)
Presence of
Thyroid
diseases
-0.315 (0.098)** -0.188 (0.088)* -
0.160 (0.081)*
Presence of
Primary
Hyperparathyroidism-0.059 (0.193)0.008 (0.159)Presence of Diabetes Mellitus0.077 (0.104)-
0.023 (0.086)Presence of vitamin B12 deficiency0.102 (0.136)0.047 (0.112)Presence of
other diagnosed autoimmune diseases-0.895 (0.249)**-0.537 (0.208)*-0.565 (0.204)*Thyroid
stimulating hormone level0.013 (0.008)0.011 (0.007)DAS28-CRP at time of diagnosis0.724
(0.027)**0.711 (0.029)**0.715 (0.029)***P value <0.05, ** P value <0.005
Conclusions: RA patients are at increased risk of specific comorbidities with pos-
sible impact on the treatment outcome. The authors, therefore, recommend to do
periodical assessment of comorbidities to diagnose concurrent comorbid dis-
eases as early as possible.
REFERENCES:
[1] Emamifar A, et al. Thyroid disorders in patients with newly diagnosed
rheumatoid arthritis is associated with poor initial treatment response eval-
uated by disease activity score in 28 joints-C-reactive protein (DAS28-
CRP): An observational cohort study. Medicine (Baltimore) 2017;96:e8357.
[2] Emamifar A, et al. Patients with newly diagnosed Rheumatoid Arthritis are
at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta
Reumatol Port 2017 [Epub ahead of print].
924 Saturday, 16 June 2018 Scientific Abstracts
on February 5, 2021 by guest. Protected by copyright.http://ard.bmj.com/Ann Rheum Dis: first published as 10.1136/annrheumdis-2018-eular.5090 on 12 June 2018. Downloaded from
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Microorganisms inhabiting human body form a complex ecosystem. The mutual influence of the microbiome and the immune system of the host constitute the basis for numerous diseases, e.g. pseudomembranous colitis, inflammatory bowel disease, type 1 diabetes, atopic diseases, obesity, reactive arthritis. New molecular diagnostic methods and multi-center studies may help in understanding of the role of microbiota in health and disease. Rheumatoid arthritis has a multi-faceted etiology, and its causes are not entirely understood. There are indications for the influence of microbiomes of oral cavity, intestines, lungs and urinary tract on the development of rheumatoid arthritis. Interactions between microorganisms and human immune system play role in the pathogenesis of the disease.
Article
Full-text available
To determine the prevalence of thyroid disorders among newly diagnosed rheumatoid arthritis (RA) patients and evaluate the association between clinical characteristics of RA and thyroid disorders, and also initial treatment response in the RA patients with thyroid disorders. Newly diagnosed, adult RA patients who were diagnosed according to the new 2010 American College of Rheumatology/European League Against Rheumatism criteria since January 1, 2010, were included. Patients’ demographic data, serology results including immunoglobulin M rheumatoid factor (IgM RF), anticyclic citrullinated peptide antibody (anti-CCP), and antinuclear antibody (ANA), and also disease activity score in 28 joints-C-reactive protein at the time of diagnosis and after 4 months (±1–2 months) of treatment initiation were extracted from Danish Danbio Registry. Patients’ electronic hospital records for the past 10 years were reviewed to reveal if they had been diagnosed with thyroid disorders or they had abnormal thyroid test. In all, 439 patients were included, female 60.1%, mean age 64.6 ± 15.0 years and disease duration 2.6 ± 1.7 years. Prevalence of thyroid disorders was 69/439 (15.7%) and hypothyroidism was the most frequent disorder (30.4%). The presence of thyroid disorders among RA patients was significantly associated with female sex (P < .001), ANA positivity (P = .04), and anti-CCP ≥100 EU/mL (P = .05). Furthermore, RA patients with thyroid disorders had significantly poorer initial response to RA treatment compared with patients with isolated RA after 4 months of treatment (P = .02). There were no associations between thyroid disorders and age, disease duration, and also IgM RF positivity. Presence of thyroid disorders in RA patients is suggestive of a more aggressive disease and poor outcome, with direct effect on initial treatment response. To diagnose concurrent thyroid disorders at an earlier stage, routine measurement of serum thyroid-stimulating hormone is recommended in all RA patients at the time of diagnosis and with yearly interval thereafter.
Article
Full-text available
Aims: To reveal the prevalence of Diabetes Mellitus (DM) in patients with newly diagnosed Rheumatoid Arthritis (RA) and evaluate the association between clinical characteristics of RA and DM as well as treatment response in newly diagnosed RA patients with DM. Methods: Newly diagnosed, adult, RA patients, who were registered in Danish Danbio since 1st January 2010, were included. Patients' demographics, serology results including rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP) and antinuclear antibody (ANA) as well as disease activity score in 28 joints-C-reactive protein (DAS28-CRP) at the time of diagnosis and after 4 months (±1-2 months) of treatment initiation were extracted from Danbio Registry. To reveal the presence of DM, patients' electronic medical records were reviewed. The prevalence of DM in our patients was compared (using an age- and gender-matched analysis) with that expected from Danish population. Results: of 439 included patients, 60.1% were female, mean of age 64.6±15.0 years and RA disease duration 2.6±1.7 years. Prevalence of DM was 57/439 (12.9%), herein type II DM 52 (91.2%) and type I DM 5 (8.8%). Except for two patients, diagnosis of DM was established prior to the diagnosis of RA. The prevalence of DM in newly diagnosed RA patients of all ages was significantly increased versus that expected from Danish population (RR=2.21, CI=1.40-3.42, P min 0.001). In addition, prevalence of DM was significantly increased with more than twice of the expected for RA patients aged 65-84. Both genders showed increased risk of DM after subgroup analysis. The presence of DM in RA patients was significantly associated with age (P min 0.001) and RA disease duration ≥4 years (P =0.05). We did not find any significant associations between presence of DM and gender, RF, anti-CCP as well as ANA. Additionally, presence of DM in the RA patients was not a negative predictor of treatment response measured by the European League Against Rheumatism (EULAR) response criteria and ∆DAS28-CRP. Conclusion: Newly diagnosed RA patients are at higher risk of DM (13% versus 5.7% in Denmark), and a high index of suspicion must be kept.
Article
Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).
Article
To the Editor: Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is used in Japan for the treatment of patients with active rheumatoid arthritis that is resistant to methotrexate.1 Methotrexate is used only for patients who do not have a response to or cannot tolerate other disease-modifying antirheumatic drugs, such as sulfasalazine. Infliximab is not used as primary therapy for rheumatoid arthritis in Japan. Strict postmarketing surveillance of infliximab and etanercept, a drug that blocks the action of TNF, revealed incidences of pneumocystis pneumonia in Japanese patients with rheumatoid arthritis that were higher (0.4% and 0.2%, respectively) than . . .